Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status

Nitin Jain; Jorge Cortes; Alfonso Quintás-Cardama; Taghi Manshouri; Raja Luthra; Guillermo Garcia-Manero; Hagop Kantarjian; Srdan Verstovsek

doi:10.1016/j.leukres.2008.10.004

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status

Nitin Jain, Jorge Cortes, Alfonso Quintás-Cardama, Taghi Manshouri, Raja Luthra, Guillermo Garcia-Manero, Hagop Kantarjian, Srdan Verstovsek

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-platelet-derived growth factor-α (PDGFRα) rearrangement. We treated with imatinib 18 HES patients (11 PDGFRα-negative and 7 PDGFRα-status unknown). One patient with unknown PDGFRα status achieved complete hematologic response, and two (one PDGFRα negative and one status unknown) achieved partial hematologic response. Our results confirm low response rate to imatinib in HES patients with unknown or negative PDGFRα status, and underscore the need for new therapeutic options for this disorder.

Original language	English (US)
Pages (from-to)	837-839
Number of pages	3
Journal	Leukemia Research
Volume	33
Issue number	6
DOIs	https://doi.org/10.1016/j.leukres.2008.10.004
State	Published - Jun 2009
Externally published	Yes

Keywords

FIP1L1-PDGFRα
Geevec
Hypereosinophilic syndrome
Imatinib
Tyrosine kinase inhibitor

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2008.10.004

Cite this

@article{a1ab00b8b68d405b9b7fc8d584c19028,

title = "Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status",

abstract = "Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-platelet-derived growth factor-α (PDGFRα) rearrangement. We treated with imatinib 18 HES patients (11 PDGFRα-negative and 7 PDGFRα-status unknown). One patient with unknown PDGFRα status achieved complete hematologic response, and two (one PDGFRα negative and one status unknown) achieved partial hematologic response. Our results confirm low response rate to imatinib in HES patients with unknown or negative PDGFRα status, and underscore the need for new therapeutic options for this disorder.",

keywords = "FIP1L1-PDGFRα, Geevec, Hypereosinophilic syndrome, Imatinib, Tyrosine kinase inhibitor",

author = "Nitin Jain and Jorge Cortes and Alfonso Quint{\'a}s-Cardama and Taghi Manshouri and Raja Luthra and Guillermo Garcia-Manero and Hagop Kantarjian and Srdan Verstovsek",

year = "2009",

month = jun,

doi = "10.1016/j.leukres.2008.10.004",

language = "English (US)",

volume = "33",

pages = "837--839",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status

AU - Jain, Nitin

AU - Cortes, Jorge

AU - Quintás-Cardama, Alfonso

AU - Manshouri, Taghi

AU - Luthra, Raja

AU - Garcia-Manero, Guillermo

AU - Kantarjian, Hagop

AU - Verstovsek, Srdan

PY - 2009/6

Y1 - 2009/6

N2 - Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-platelet-derived growth factor-α (PDGFRα) rearrangement. We treated with imatinib 18 HES patients (11 PDGFRα-negative and 7 PDGFRα-status unknown). One patient with unknown PDGFRα status achieved complete hematologic response, and two (one PDGFRα negative and one status unknown) achieved partial hematologic response. Our results confirm low response rate to imatinib in HES patients with unknown or negative PDGFRα status, and underscore the need for new therapeutic options for this disorder.

AB - Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-platelet-derived growth factor-α (PDGFRα) rearrangement. We treated with imatinib 18 HES patients (11 PDGFRα-negative and 7 PDGFRα-status unknown). One patient with unknown PDGFRα status achieved complete hematologic response, and two (one PDGFRα negative and one status unknown) achieved partial hematologic response. Our results confirm low response rate to imatinib in HES patients with unknown or negative PDGFRα status, and underscore the need for new therapeutic options for this disorder.

KW - FIP1L1-PDGFRα

KW - Geevec

KW - Hypereosinophilic syndrome

KW - Imatinib

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=63349097828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63349097828&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2008.10.004

DO - 10.1016/j.leukres.2008.10.004

M3 - Article

C2 - 19013640

AN - SCOPUS:63349097828

SN - 0145-2126

VL - 33

SP - 837

EP - 839

JO - Leukemia Research

JF - Leukemia Research

IS - 6

ER -

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this